Ostarine - Actemra (Tocilizumab) Interaction

Interaction Details

Tocilizumab is classified as belonging to the following category: Hepatotoxic Drugs

Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Some clinical research shows that ostarine can increase alanine aminotransferase, a marker of liver damage, in some patients. Additionally, the U.S. Food and Drug Administration warns that supplements containing SARMs, such as ostarine, have been associated with reports of liver toxicity and there are at least two reports of drug-induced liver injury attributed to the use of ostarine.

Interaction Rating

Likelihood of Occurrence

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

• Warning Letter: Ironmag Labs 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582464.htm Accessed: November 1, 2017
• Warning Letter: Panther Sports Nutrition 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm581630.htm. Accessed: November 1, 2017
• Warning Letter: Infantry Labs LLC 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582685.htm. Accessed: November 1, 2017
• Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14(4):335-45.
• Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II tri
• Bedi H, Hammond C, Sanders D, Yang HM, Yoshida EM. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J 2021;8(1):e00518.
• Weinblatt D, Roy S. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator. J Med Cases 2022;13(5):244-248.

Tocilizumab Overview

• Tocilizumab injection is used alone or in combination with other medications to relieve the symptoms of certain types of arthritis and other conditions including:

  • rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults who have not been helped by other disease-modifying antirheumatic drugs (DMARDs),

  • giant cell arteritis (a condition that causes swelling of blood vessels, especially in the scalp and head) in adults,

  • systemic sclerosis-associated interstitial lung disease (SSc-ILD; also known as scleroderma-associated ILD: a lung disease that involves scarring of the lungs) in adults,

  • polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children 2 years of age or older.

  • systemic juvenile idiopathic arthritis (SJIA; a condition in children that causes inflammation in different areas of the body, causing fever, joint pain and swelling, loss of function, and delays in growth and development) in children 2 years of age or older,

  • cytokine release syndrome (a severe and possibly life-threatening reaction) in adults and children 2 years of age or older after receiving certain immunotherapy infusions.

• Tocilizumab injection is in a class of medications called interleukin-6 (IL-6) receptor inhibitors. It works by blocking the activity of interleukin-6, a substance in the body that causes inflammation.

Ostarine - More Interactions

Ostarine interacts with 581 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.